Key result
H-FAME significantly improved cardiac function in mice post-myocardial infarction, restoring left ventricular ejection fraction to 74.79% compared to 44.11% in the untreated group at 21 days.
Why the study?
Rapid and safe restoration of cardiomyocyte mitochondrial function remains a major challenge in myocardial infarction therapy.
Does H-FAME nanomedicine improve cardiac functional recovery and reduce infarct size in a preclinical mouse model of myocardial infarction?
Does H-FAME nanomedicine improve cardiac functional recovery and reduce infarct size in a preclinical mouse model of myocardial infarction?
H-FAME is a novel targeted nanomedicine that effectively restores mitochondrial bioenergetics, suppresses oxidative stress, limits infarct size, and restores cardiac function in a mouse model of myocardial infarction.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for mitochondrial-targeted nanomedicine post-MI; leaves open translation to larger models and clinical trials.
In myocardial infarction (MI), mitochondrial dysfunction acts as a core mechanism linking energy failure to multiple downstream pathological processes, ultimately determining cardiomyocyte fate and cardiac function. However, the rapid and safe restoration of cardiomyocyte mitochondrial function remains a major challenge in MI therapy. Herein, we present a heart-homed fast acting mitochondrial-function enhancer (H-FAME), rationally engineered to achieve sequential targeting from ischemic myocardial tissue to cardiomyocyte mitochondria. By synergistically modulating mitochondrial membrane potential (MMP) and oxidative stress, H-FAME stabilizes mitochondrial function, thereby attenuating cardiomyocyte loss, inflammation, and fibrosis and ultimately promoting functional recovery after MI. In summary, H-FAME provides a robust approach for energy homeostasis restoration, and lays the foundation for the development of related mitochondrial protective drugs to treat MI. • Mitochondrial dysfunction and oxidative stress drive cardiomyocyte injury after MI. • H-FAME was developed to reconstruct mitochondrial bioenergetics after MI. • H-FAME enables sequential myocardial-mitochondrial targeting and coordinated regulation of MMP and oxidative stress. • This fast mitochondrial rescue suppresses inflammation, fibrosis, and apoptosis, leading to robust cardiac functional recovery.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2026) studied Myocardial Infarction. H-FAME (heart-homed fast acting mitochondrial-function enhancer) vs. MI untreated, FAME, GP, NAC, and MitoQ was evaluated on Left ventricular ejection fraction (LVEF) at 21 days post-myocardial infarction (p=<0.001). H-FAME significantly improved cardiac function in mice post-myocardial infarction, restoring left ventricular ejection fraction to 74.79% compared to 44.11% in the untreated group at 21 days.
Synapse has enriched 10 related papers. Consider them for comparative context: